Donna Boyce

Senior Vice President Global Regulatory Affairs at Pfizer

Donna Boyce is an experienced regulatory affairs professional with a strong background in vaccine development and strategy. Currently serving as the Senior Vice President of Global Regulatory Affairs at Pfizer since May 2013, Donna leads the regulatory strategy for the Pfizer Vaccine Portfolio. Prior to this role, Donna held various positions at GSK from February 2001 to May 2013, including Head of North America Vaccines Regulatory Affairs and CMC Director for the Pediatric portfolio. Donna began a career at Merck from September 1995 to September 2001 as the Regulatory CMC head for Pneumococcal Vaccines.

Location

Ambler, United States

Links

Previous companies


Org chart


Teams


Offices

This person is not in any offices


Pfizer

614 followers

Pfizer Inc. is a research-based, global biopharmaceutical company. They apply science and their global resources to bring therapies to people that extend and significantly improve their lives through the discovery, development, manufacture, marketing, sale and distribution of biopharmaceutical products worldwide. They work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Pfizer collaborates with healthcare providers, governments and local communities to support and expand access to reliable, affordable healthcare around the world. Pfizer was founded in 1942. Most of Pfizer’s revenues come from the manufacture and sale of biopharmaceutical products. They believe that their medicines and vaccines provide significant value for healthcare providers and patients, through improved treatment of diseases, improvements in health, wellness and productivity as well as by reducing other healthcare costs, such as emergency room or hospitalization. Pfizer is committed to fulfilling their purpose: Breakthroughs that change patients’ lives. Their purpose fuels everything they do and reflects both their passion for science and commitment to patients. Pfizer’s growth strategy is driven by five “Bold Moves” that help them deliver breakthroughs for patients and create value for shareholders and other stakeholders: 1. Unleash the power of our people; 2. Deliver first-in-class science; 3. Transform our go-to-market model; 4. Win the digital race in pharma; and 5. Lead the conversation.